Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “buy” rating reaffirmed by equities researchers at Cowen and Company in a report issued on Thursday.

The analysts wrote, “Adaptimmune Therapeutics Receives a Buy from Cowen & Co. | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=07a193bd66&wpp_id=459633’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Adaptimmune Therapeutics Receives a Buy from Cowen & Co.”

Several other research analysts also recently issued reports on the stock. Bank of America Corp. downgraded shares of Adaptimmune Therapeutics PLC from a “neutral” rating to an “underperform” rating in a report on Monday, October 24th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Monday, October 10th. Finally, Raymond James Financial Inc. initiated coverage on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 30th. They issued an “outperform” rating and a $16.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $14.35.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) opened at 5.01 on Thursday. The firm’s market cap is $354.63 million. The firm’s 50-day moving average price is $5.61 and its 200 day moving average price is $7.74. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $12.85.

A number of institutional investors have recently added to or reduced their stakes in ADAP. JPMorgan Chase & Co. bought a new position in shares of Adaptimmune Therapeutics PLC during the third quarter worth about $149,000. Glenmede Trust Co. NA raised its position in shares of Adaptimmune Therapeutics PLC by 574.9% in the second quarter. Glenmede Trust Co. NA now owns 20,923 shares of the company’s stock worth $170,000 after buying an additional 17,823 shares during the last quarter. Springbok Capital Management LLC bought a new position in shares of Adaptimmune Therapeutics PLC during the first quarter worth about $202,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Adaptimmune Therapeutics PLC by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 108,995 shares of the company’s stock worth $888,000 after buying an additional 3,519 shares during the last quarter. Finally, New Leaf Venture Partners L.L.C. bought a new position in shares of Adaptimmune Therapeutics PLC during the second quarter worth about $1,035,000. Hedge funds and other institutional investors own 44.36% of the company’s stock.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

5 Day Chart for NASDAQ:ADAP

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.